Why they built it
The founders believed people failed to improve their health not because they lacked data, but because they lacked clear, actionable next steps. They first envisioned a pure stress monitor for hypertension and heart disease, then expanded to a wristband covering nutrition, stress, exercise and sleep that would passively track behavior and tell users what to do each day.
Why it didn't work out
Airo cancelled its 2013 pre-orders within a month after market feedback that it lacked proof its spectroscopic nutrition tracking would work as advertised. After rebuilding around HRV-based stress tracking and joining Y Combinator Summer 2016, it recorded only $125,000 in lifetime funding with a two-person team and no documented post-YC raise, then quietly ceased operations.
What went wrong
Most important first.
- 1
Launched pre-orders with unproven core technology Technology
At the October 28, 2013 launch the team had no working prototype, no app and no investors, and experts called the wristband spectrometer nutrition claims highly questionable, leading to cancellation and refunds on November 22, 2013.
- 2
Insufficient capital for hardware Capital
Total lifetime funding was $125,000 across two rounds with no post-YC round documented, a base the report notes was unworkable for tooling, manufacturing and an initial production run.
- 3
Team too small to ship hardware Team
The YC-era team was two people, Naman Kumar and Maryam Jahed, which could not cover industrial design, firmware, app development, supply chain and support in parallel.
- 4
Absorbed by better-capitalized smartwatches Competition
Apple Watch Series 2 and Fitbit's Charge 2 with its Relax HRV feature both launched in September 2016 at $199-$349, comparable to Airo's $200 device, offering stress monitoring as one feature among many.
What could be different today
- Workplace wellness distribution through employers already exists, exemplified by Headspace for Employers offering mindfulness resources and enterprise services.
- Sensor-linked stress tools combining heart-rate and HRV signals with journal entries and breathwork already exist, exemplified by WHOOP's Stress Monitor.
- FDA's January 2026 general-wellness guidance describes a policy for low-risk healthy-lifestyle products, which frames review of intended claims and risks before deployment.